| Market Cap | 608.06M | P/E | - | EPS this Y | -11.80% | Ern Qtrly Grth | - |
| Income | -62.38M | Forward P/E | -12.23 | EPS next Y | 33.30% | 50D Avg Chg | 9.00% |
| Sales | 21.71M | PEG | - | EPS past 5Y | - | 200D Avg Chg | 25.00% |
| Dividend | N/A | Price/Book | 1.78 | EPS next 5Y | - | 52W High Chg | -50.00% |
| Recommedations | 1.70 | Quick Ratio | 4.53 | Shares Outstanding | 118.16M | 52W Low Chg | 175.00% |
| Insider Own | 5.96% | ROA | -13.95% | Shares Float | 96.04M | Beta | - |
| Inst Own | 69.52% | ROE | -19.87% | Shares Shorted/Prior | 8.25M/7.10M | Price | 5.26 |
| Gross Margin | 100.00% | Profit Margin | -287.29% | Avg. Volume | 609,317 | Target Price | 10.00 |
| Oper. Margin | -247.29% | Earnings Date | Nov 7 | Volume | 640,637 | Change | -5.05% |
OmniAb, Inc., a biotechnology company, engages in the discovery and provision of therapeutic antibody discovery technologies in the United States. The company's technology platform creates and screens diverse antibody repertoires and identify optimal antibodies for partners' drug development efforts. Its OmniAb platform is the biological intelligence of proprietary transgenic animals, including OmniRat, OmniChicken, and OmniMouse that have been genetically modified to generate antibodies with human sequences to facilitate development of human therapeutic candidates. The company's OmniFlic, a bispecific rat, and OmniClic, a bispecific chicken, designed for discovery of bispecific antibody applications; OmniTaur, which provides unique structural characteristics of cow antibodies for complex targets; and OmniDeep, a suite of in silico, an AI and machine learning tools for therapeutic discovery and optimization through various technologies and capabilities. OmniAb, Inc. was founded in 2012 and is headquartered in Emeryville, California.
| Benchmark | Buy | Aug 19, 24 |
| RBC Capital | Outperform | Aug 16, 24 |
| HC Wainwright & Co. | Buy | Aug 12, 24 |
| Benchmark | Buy | May 14, 24 |
| Truist Securities | Buy | Mar 26, 24 |
| Benchmark | Buy | Mar 22, 24 |
| HC Wainwright & Co. | Buy | Mar 21, 24 |
| RBC Capital | Outperform | Mar 21, 24 |
| Benchmark | Buy | Nov 14, 23 |
| Insider Trades | Relationship | Date | Transactions | Cost($) | #Shares | Value($) | #Share Own | SEC Form 4 |
|---|---|---|---|---|---|---|---|---|
| FOEHR MATTHEW W | Chief Executive Offi.. Chief Executive Officer | Dec 12 | Buy | 5.05 | 200,000 | 1,010,000 | 2,645,442 | 12/13/23 |
| FOEHR MATTHEW W | President and CEO President and CEO | Nov 10 | Buy | 4.2686 | 95,000 | 405,517 | 2,427,919 | 11/13/23 |
| FOEHR MATTHEW W | President and CEO President and CEO | Aug 14 | Buy | 5.48 | 45,000 | 246,600 | 2,332,919 | 08/15/23 |
| FOEHR MATTHEW W | Chief Executive Offi.. Chief Executive Officer | Jun 09 | Buy | 4.52 | 115,000 | 519,800 | 2,574,009 | 06/12/23 |
| HIGGINS JOHN L | Director Director | May 18 | Sell | 3.89 | 50,000 | 194,500 | 2,462,686 | 05/19/23 |
| HIGGINS JOHN L | Director Director | May 18 | Option | 3.68 | 50,000 | 184,000 | 2,512,686 | 05/19/23 |
| Cochran Jennifer R. | Director Director | Dec 06 | Buy | 3.754 | 22,250 | 83,526 | 77,476 | 12/08/22 |
| FOEHR MATTHEW W | President & CEO President & CEO | Nov 30 | Buy | 3.3878 | 300,000 | 1,016,340 | 1,705,350 | 12/01/22 |
| GUSTAFSON KURT A | EVP, Finance and CFO EVP, Finance and CFO | Nov 28 | Buy | 2.81 | 10,000 | 28,100 | 170,062 | 11/29/22 |
| Patel Sunil | Director Director | Nov 09 | Buy | 2.77 | 43,000 | 119,110 | 215,512 | 11/10/22 |
| FOEHR MATTHEW W | President & CEO President & CEO | Nov 09 | Buy | 2.7616 | 100,000 | 276,160 | 1,405,350 | 11/09/22 |